Treatment Cost of Metastatic Colon CA in Turkey Kockaya, Guvenc (1); Polat, Mine (2); Özet, Ahmet (3); Vural, İsmail Mert (1); Akbulat, Akif (1); Akar,

Slides:

Advertisements

Similar presentations

Advertisements

Mario Scartozzi Clinica di Oncologia Medica Ancona HIGHLIGHTS IN COLORECTAL CANCER MANAGEMENT TREATMENT OF METASTATIC DISEASE.

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉財團法人台灣癌症臨床研究發展基金會.

Direct Cost Survival Analysis of Treatment of Metastatic Colorectal Cancer Yu-Ning Wong 1, Neal J. Meropol 1, Daniel Sargent 2, Richard Goldberg 3, J.

Overview of Drug Tracking System (ITS) in the Pharmacies of Ankara: Preliminary Research Yildirim, Fikri (1); Kockaya, Guvenc (1); Yildirim Ocal, Julide.

Aakash H. Gajjar, MD, FACS Assistant Professor of Surgery Colon & Rectal Surgery University of Texas Medical Branch Galveston, Texas February 10 th, 2014.

A Quality-Adjusted Price Index for Colorectal Cancer Drugs Claudio Lucarelli Sean Nicholson Cornell University June 2, 2007.

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

Off-Label and Non-Licensed Endocrinology Medicine Use in Turkey: A Retrospective Analysis of Computer Records in the Turkish Ministry of Health Kockaya,

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.

Conservative treatment of liver metastasis

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Diabetes mellitus and the incidence and time to onset of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer: A pooled.

RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL ASSESSING SURVIVAL AT 3 YEARS OF POLYVINYL ALCOHOL MICROSPHERES PRELOADED WITH IRINOTECAN (DEBIRI) VS. FOLFIRI.

Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,

Simplification of Bevacizumab Administration: Do we need 90, 60, or even 30 minute infusion times? LB Saltz, K-Y Chung, D Reidy, J Timoney, V Park, E.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

An update on biological therapies in colorectal cancer Mount Vernon Cancer Network Sept 05 Mark Harrison.

Xeloda ® plus oxaliplatin: rationale in colorectal cancer (CRC)  Oxaliplatin is active in CRC, especially when combined with 5-FU/leucovorin (LV)  Superior.

INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.

Phase III studies of Xeloda® in colorectal cancer (CRC)

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

Therapeutic Significance of D-dimer Cut-off Level of more than 3 µg/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Future directions for Avastin ® in colorectal cancer (CRC) Fairooz Kabbinavar David Geffen School of Medicine at UCLA Los Angeles, USA.

Clara Natoli, MD Professor of Medical Oncology University G. D ' Annunzio Chieti - Pescara Clara Natoli, MD Professor of Medical Oncology University G.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.

0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,

XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.

Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,

Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC)

Riccardo Giampieri Scuola di Specializzazione Oncologia Università Politecnica delle Marche Ancona How to manage patients with mutated KRAS tumors.

Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.

Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.

A Phase I Study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer May Cho, Dean Lim, Timothy Synold, Paul Frankel, Lucille Leong,

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

CCO Independent Conference Coverage

Adjuvant therapy in colon cancer

*University Hospital Gasthuisberg, Leuven, Belgium

TREATMENT ARM B: Cycles 1–3: Cycles 4+: 5-FU continuous infusion

Systemic treatment for colorectal cancer

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Reviewer: Dr Scott Berry Date posted: June 21, 2007

Jordan Berlin Co-Director, GI Oncology Program

or other irinotecan-based regimens

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Targeted Therapies for Hepatocellular Carcinoma

1Cancer Research UK, Glasgow, United Kingdom

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

and the NSABP Investigators

1Sunnybrook Health Sciences Centre, University of Toronto, Canada

Colorectal Cancer in Older Patients Key Issues

Presentation transcript:

Treatment Cost of Metastatic Colon CA in Turkey Kockaya, Guvenc (1); Polat, Mine (2); Özet, Ahmet (3); Vural, İsmail Mert (1); Akbulat, Akif (1); Akar, Halil (1); Kerman, Saim (1) 1: General Directorate of Pharmaceuticals and Pharmacy, Turkey; 2: Baskent University, Turkey; 3: Gazi University, Turkey

Abstract Problem statement: Colon cancer is the third most common in the top cancer incidence list—212,000 patients die in Europe per year because of colon cancer. In Turkey 150, ,000 new cancer patients are diagnosed every year, 13% of whom have colon cancer. Metastasis will occur among 50% of the patients who are newly diagnosed and operated on. It is believed that metastasis will occur in 9,000-10,000 colon cancer patients every year in Turkey. Objective: Survival appears to be prolonged to more than 20 months with the new pharmaceuticals; however, these new pharmacuticals increase the total cost. The aim of our study is to calculate colon cancer treatment options for Turkey.

Abstract Method: Gazi University Hospital treatment protocols for colon cancer treatment were used. The cost of Irinotekan-Erbutix, B-IFL, Bevacizumab-FUFA, XELOX, XELIRI, IFL-Cetuximab, Irinotekan, FOLFIRI-Doillard, FOLFOX-4, FOLFIRI-Tornigard, Raltrexed, FUFA, and Inf-5 FU (Degramount) protocols were calculated. The cost of pharmaceuticals and medical treatment used in the protocols were taken from the Social Security Institution’s website. The exchange rate was USD 1 for TL 1.5. Results: Inf-5 FU (Degramount) (USD 220) had the lowest cost for 1 cycle, followed by FUFA (USD 342), FOLFIRI-Tornigard (USD 390), Raltrexed (USD 504), FOLFIRI-Doillard (USD 521), Irinotekan (USD 619), FOLFOX-4 (USD 704), XELOX (USD 880), XELIRI (USD 947), IFL (USD 1785), Bevacizumab-FUFA (USD 2730), B-IFL (USD 5203), and Irinotekan- Cetixumab (USD 11625).

Abstract Conclusion: Every treatment protocol is administered for 6 cycles for each patient depending on the disease’s stage. If a treatment protocol is not successful, the patient will be given a different protocol. Different combinations of cycles can be administered, depending on the responses of the patients. Although Irinotekan- Cetixumab had the highest cycle cost, further analysis is needed to compare the cost and effectiveness of different protocols and combinations. Funding source: There was not any funding source or conflicyt of interest for the manuscript

Introduction & Objectives Generally, colon and rectum cancers are referred as colorectal cancer (CRC). Colorectal cancer develops slowly in years. In Turkey, incidance of cancer is 173,85 in per , 7,1 % of whom are diagnosed to have developed colon cancer. In addition to prevelance and great mortality numbers metastases will develop in 30– 40% of CRC patients. This metastase rate can cause mortality also. In the light of these, it could be said that metastase will occur in colon cancer patients every year in Turkey. Cost of treatment of CRC is high also. The aim of our study is to calculate the cost of colon cancer treatment protocols and cost of per year with different combinations of protocols for Turkey.

Methods Gazi University Hospital treatment protocols for colon cancer treatment were used. The cost of Irinotekan-Erbutix, B-IFL, Bevacizumab- FUFA, XELOX, XELIRI, IFL-Cetuximab, Irinotekan, FOLFIRI-Doillard, FOLFOX-4, FOLFIRI-Tornigard, Raltrexed, FUFA, and Inf-5 FU (Degramount) protocols were calculated. The cost of pharmaceuticals and medical treatment used in the protocols were taken from the Social Security Institution’s website. The exchange rate was USD 1 for TL 1.5.

Cost of Pharmaceuticals MoleculesPackage Average Price (in $ USD) 5-Fluorourasil500 mg2,93 (2,71-3,12) 1000 mg5,50 (5,34-5,82) Bevacizumab100 mg307, mg1140,55 Cetuximab100 mg mg1533,33 Folinik asit40 mg0,67 (0,56-0,76) Irinotekan40 mg58, mg135,66 Kapesitabin150 mg 60 tbl59, mg 60 tbl344,57 Oxaliplatin50 mg 108,28 (105, ,61) 100 mg 215,31 (210,8- 242,41) Raltireksed2 mg142,30

Protocols Table 1: Protocols ProtocolPharmaceuticalAdministration1.D2.D3.D4.D5.D14.D FUFA (5FU/LV) (1 amp Metpamid, 1 amp Decort, 1 amp Systal and laboratories) 5-Fluorourasil (425 mg/m 2 ) 15 mn. İnfusion in 250 cc SF Folinik asit (20 mg/m 2 ) i.v. push+++++ FOLFIRI (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Decort + 1 amp Systral and laboratories) Irinotekan (180 mg/m 2 ) 90 mn. infusion in 250cc SF + Folinik asit (200 mg/m 2 ) 2 hrs infusion in 250 cc SF ++ 5-FU (400 mg/m 2 ) 15 mn. in 250cc SF ++ 5-FU (600 mg/m 2 ) 22 hrs infusion in 1000 cc SF ++ FOLFOX (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) Oxaliplatin (85 mg/m 2 ) 2 hrs infusion in 1000 cc %5 dextroz + Folinik asit (200 mg/m 2 ) 2 hrs infusion in 250 cc %5 dextroz ++ 5-FU (400 mg/m 2 ) 15 mn. infusion in 250 cc SF ++ 5-FU (600 mg/m 2 ) 22 hrs. İnfusion in 1000 cc SF ++ Bevacizumab/FUFA (1 amp Metpamid, 1 amp Dekort and 1 amp Systral) Bevacizumab (5 mg/kg) in 100 cc SF++ 5-Fluorourasil (425 mg/m 2 ) 15 mn. infusion in 250 cc SF Folinik asit (20 mg/m 2 ) i.v. push+++++

Protocols ProtocolPharmaceutical Administratio n 1.D8.D15.D22.D29.D Bevacizumab/FOLFIRI (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Decort + 1 amp Systral and laboratories) Irinotekan (125 mg/m 2 ) 90 mn. infusion in 250 cc SF ++++ Folinik asit (20 mg/m 2 ) i.v. push FU (500 mg/m 2 ) 15 mn infusion in 250 cc SF ++++ Bevacizumab (5 mg/kg) in 100 cc SF+++ Bevacizumab/FOLFOX (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) Bevacizumab (5 mg/kg) in 100 cc SF++ Oxaliplatin (85 mg/m 2 ) 2 hrs infusion in 1000 cc %5 dextroz + Folinik asit (200 mg/m 2 ) 2 hrs infusion in 250 cc %5 dextroz ++ 5-FU (400 mg/m 2 ) 15 mn. infusion in 250 cc SF ++ 5-FU (600 mg/m 2 ) 22 hrs. İnfusion in 1000 cc SF ++ Irinotekan (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) (350 mg/m 2 ) 90 mn infusion in 250 cc SF + İrinotekan +Cetuximab (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) İrinotekan (200mg) 90 mn infusion in 250 cc SF ++ Cetuximab (begining 700 mg, maintenance 500 mg) 120 mn iv infusion +++ Raltireksed (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) Raltireksed (3 mg/m 2 ) 15 mn infusion 250 cc SF + Xeliri (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) Irinotekan (250 mg/m 2 ) 90 mn infusion in 250 cc SF + Kapesitabin (1500 mg/m 2 /day) 2 dose in a day++ Xelox (tropisetron 5 mg or ondansetron 4-8 mg, 1 amp Dekort, 1 amp Systral) Oxaliplatin (130 mg/m 2 ) 2 hrs infusion in 250 cc %5 dextroz + Kapesitabin (1500 mg/m 2 /gün) 2 dose in a day++

Results The lowest cost for one cycle was established by FUFA (US $ 342). It were followed by FOLFIRI (US$ 390), Raltireksed (US$ 512), Irinotekan (US$ 619), FOLFOX (US$ 704), Bevacizumab/FUFA (US$ 2730), Xelox (US$ 3685), Xeliri (US$ 3774), Bevacizumab/FOLFOX (US$ 4367), Bevacizumab/FOLFIRI (US$ 5203) and Irinotekan/Cetixumab (US$ 11625).

Cost of Protocols ProtocolsCost (in US$) FolfiriUS$ 390 RaltireksedUS$ 512 IrinotekanUS$ 619 FOLFOXUS$ 704 Bevacizumab/FUFA US$ 2730 XeloxUS$ 3685 XeliriUS$ 3774 Bevacizumab/FOLFO X US$ 4367 Bevacizumab/FOLFI RI US$ 5203 Irinotekan/CetixumabUS$ 11625

Conclusion Every treatment protocol is administered for 6 cycles for each patient depending on the disease’s stage. If a treatment protocol is not successful, the patient will be given a different protocol. Different combinations of cycles can be administered, depending on the responses of the patients. Although Irinotekan-Cetixumab had the highest cycle cost, further analysis is needed to compare the cost and effectiveness of different protocols and combinations.